Matched Placebo to Test
Sponsors
Sanofi-Aventis Research & Development, Sanofi-Aventis Recherche & Developpement
Conditions
Nervous system diseasesPruritus
Phase 3
An interventional, Phase 3 extension study to investigate long-term safety and tolerability of tolebrutinib in participants with relapsing multiple sclerosis, primary progressive multiple sclerosis, or nonrelapsing secondary progressive multiple sclerosis
WithdrawnCTIS2023-503631-18-00
Target: 75Updated: 2023-11-27
Master protocol of two randomized, double blind, placebo-controlled, multi-center, parallel group studies to evaluate the efficacy and safety of dupilumab in adult patients with chronic pruritus of unknown origin (CPUO)
RecruitingCTIS2023-508879-36-00
Start: 2022-04-28Target: 172Updated: 2026-01-15
An interventional, Phase 3 extension study to investigate long-term safety and tolerability of tolebrutinib in participants with relapsing multiple sclerosis, primary progressive multiple sclerosis, or nonrelapsing secondary progressive multiple sclerosis
Active, not recruitingCTIS2023-503631-18-01
Start: 2024-05-20Target: 1405Updated: 2025-11-11